![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001
|
|
|
Reported by Jules Levin
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Timothy Eley1, Sofia Caamano1, Jill Denning1, Karen Sims1, Richard Larouche2, William Symonds1, Patricia Mendez1
1Arbutus Biopharma Corporation, Burnaby, BC, Canada. 2.InVentiv Health, Quebec, QC, Canada
![1110171](../images/111017/111017-1/1110171.gif)
![1110172](../images/111017/111017-1/1110172.gif)
![1110173](../images/111017/111017-1/1110173.gif)
![1110174](../images/111017/111017-1/1110174.gif)
![1110175](../images/111017/111017-1/1110175.gif)
![1110176](../images/111017/111017-1/1110176.gif)
![1110177](../images/111017/111017-1/1110177.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|